All

MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease
18 March 2025

MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
Citryll demonstrates a broader therapeutic potential for cit-013 in the treatment of inflammatory disorders
24 February 2025

Citryll demonstrates a broader therapeutic potential for cit-013 in the treatment of inflammatory disorders

Breakthrough study published in Frontiers in Immunology demonstrates CIT-013’s effectiveness against additional types of extracellular traps, expanding potential therapeutic...

Read the press release
SeaWeed Concept raises 2 million euros to expand production of seaweed for human consumption
21 February 2025

SeaWeed Concept raises 2 million euros to expand production of seaweed for human consumption

SeaWeed Concept, start-up specializing in the use of lacto-fermented seaweed for human consumption, has just raised 2 million euros from the Paris-based Blue Forward Fund. This...

Read more
Ekstere raises €2,4 million to make cycling truly sustainable !
12 February 2025

Ekstere raises €2,4 million to make cycling truly sustainable !

Entry of Ekstere into the Sport and Performance Capital funds of Seventure Partners.
Structuring the second-hand bike market through listing.
Make sustainable...

Read the press release
Anybuddy raises €2M with Seventure Partners’ Sport & Performance Capital fund and becomes the benchmark in racquet sports by accelerating its focus on padel.
6 February 2025

Anybuddy raises €2M with Seventure Partners’ Sport & Performance Capital fund and becomes the benchmark in racquet sports by accelerating its focus on padel.

Anybuddy, France's leading racquet sports booking platform, has announced a €2 million round of financing to support its expansion and enhance its service offering.
By...

Read the press release
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
30 January 2025

Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors

Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa...

Read more
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
21 January 2025

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
Extending Insights to the Small Intestine: Cmbio™ Teams Up with Nimble Science
21 January 2025

Extending Insights to the Small Intestine: Cmbio™ Teams Up with Nimble Science

Cmbio™, a global leader in multi-omics science and digital biology, announces a strategic partnership with Nimble Science, to deliver first in class high-quality, multi-omic...

Read more
Cmbio® Acquires Eagle Genomics’ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.
10 January 2025

Cmbio® Acquires Eagle Genomics’ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.

Cmbio®, a global leader in multi-omics science and digital biology, is pleased to announce the purchase of the e[datascientist]™ software platform through an Asset Sale...

Read more
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
8 January 2025

MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease

The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of MaaT013 as...